Drug
Bay1841788 Darolutamide
Bay1841788 Darolutamide: highest development phase Phase 3, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| BAY1841788 / darolutamide (ODM-201) NCT02799602 | Phase 3 | Metastatic Hormone-sensitive Prostate Cancer |
Latest
No recent events.
Follow Bay1841788 Darolutamide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.